Translation from Preclinical Research to Clinical Trials: Brain-Gut Photobiomodulation Therapy for Alzheimer's Disease.

Alzheimer's disease amyloid electromagnetic magnetic memory neuro degenerescence neuroinflammation oxidative stress phosphorylated tau photobiomodulation photonics

Journal

Journal of integrative neuroscience
ISSN: 0219-6352
Titre abrégé: J Integr Neurosci
Pays: Singapore
ID NLM: 101156357

Informations de publication

Date de publication:
11 Mar 2024
Historique:
received: 27 09 2023
revised: 18 11 2023
accepted: 29 11 2023
medline: 28 3 2024
pubmed: 28 3 2024
entrez: 27 3 2024
Statut: ppublish

Résumé

Recently, novel non-pharmacological interventions, such as photobiomodulation (PBM) therapy, have shown promise for the treatment of Alzheimer's disease (AD). This article outlines the translation from the preclinical to clinical stages of an innovative brain-gut PBM therapy in a mouse model of AD, a pilot clinical trial involving mild-to-moderate AD patients, and a continuing pivotal clinical trial with a similar patient population. In a mouse model of AD (Aβ25-35), daily application of brain-gut PBM therapy to both the head and the abdomen produced a neuroprotective effect against the neurotoxic effects of an Aβ25-35 peptide injection by normalizing all the modified behavioral and biochemical parameters. The pilot clinical trial to evaluate brain-gut PBM therapy demonstrated the tolerability and feasibility of the novel PBM-based treatment for mild-to-moderate AD patients. Compared to the sham patients, the PBM-treated patients had lower Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) comprehension sub-scores, higher forward verbal spans, and lower Trail Making Test (TMT) Part B (TMT-B) execution times, which suggest an improvement in cognitive functions. This pilot study provided important information for the design of a novel pivotal clinical trial, currently in progress, to assess the efficacy of brain-gut PBM therapy in a larger sample of AD patients. This pivotal clinical trial could demonstrate that brain-gut PBM therapy is a safe, well-tolerated, and efficient disease-modifying treatment for mild-to-moderate AD patients and that it has medical and economic benefits.

Identifiants

pubmed: 38538226
pii: S0219-6352(23)00680-0
doi: 10.31083/j.jin2303057
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

57

Informations de copyright

© 2024 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

Guillaume Blivet is an employee of REGEnLIFE and owns equity. Jacques Touchon is a consultant for REGEnLIFE. François J. Roman is the director of FR Consulting. The authors declare no conflict of interest and the writing were not influenced by this relationship.

Auteurs

Guillaume Blivet (G)

REGEnLIFE, 75008 Paris, France.

François J Roman (FJ)

FRconsulting, 34800 Clermont l'Hérault, France.

Julien Delrieu (J)

Maintain Aging Research Team, CERPOP, Université de Toulouse, Inserm, Université Paul Sabatier, 31000, Toulouse, France.
Gérontopôle, Department of Geriatrics, Toulouse University Hospital, 31000, Toulouse, France.

Jacques Touchon (J)

Faculty of Medicine, University of Montpellier, 34000 Montpellier, France.

Classifications MeSH